Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Walter Reinisch

Showing results (61-70 of 352) with videos related to

Pageof 36
Sort By:
Alimentary Pharmacology & Therapeutics|February 15, 2022
Resolution of dominant patient-reported outcome at end of induction predicts clinical and endoscopic remission in Crohn's diseaseEmily C L Wong, Parambir S Dulai, John K Marshall, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|August 27, 2022
Predictors of Placebo Induction Response and Remission in Ulcerative ColitisEmily C L Wong, Parambir S Dulai, John K Marshall, et al.
Inflammatory Bowel Diseases|August 3, 2022
Comparative Efficacy of Infliximab vs Ustekinumab for Maintenance of Clinical Response in Biologic Naïve Crohn's DiseaseEmily C L Wong, Parambir S Dulai, John K Marshall, et al.
Plos One|May 28, 2020
Risk for development of inflammatory bowel disease under inhibition of interleukin 17: A systematic review and meta-analysisJohan Burisch, Wolfgang Eigner, Stefan Schreiber, et al.
Scandinavian Journal of Gastroenterology|August 1, 2022
End of induction patient reported outcomes predict clinical remission and endoscopic improvement with vedolizumab and adalimumab in ulcerative colitisEmily Chu Lee Wong, Badar Hasan, Parambir S Dulai, et al.
Inflammatory Bowel Diseases|November 25, 2022
Predictors of Clinical Remission to Placebo in Clinical Trials of Crohn's DiseaseEmily C L Wong, Parambir S Dulai, John K Marshall, et al.
Analytical Chemistry|January 7, 2012
Simultaneous quantification of eleven thiopurine nucleotides by liquid chromatography-tandem mass spectrometryUte Hofmann, Georg Heinkele, Sieglinde Angelberger, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|September 15, 2014
Placebo response rate in clinical trials of fistulizing Crohn's disease: systematic review and meta-analysisAlexander C Ford, Pavit Luthra, Stephen B Hanauer, et al.
Zeitschrift Fur Gastroenterologie|January 12, 2026
Post-induction serum vedolizumab levels are not associated with better maintenance outcomes in patients with Crohn's diseaseJagoda Pokryszka, Christian Primas, Michael Stadlmann, et al.
Pharmaceutics|September 28, 2021
External Model Performance Evaluation of Twelve Infliximab Population Pharmacokinetic Models in Patients with Inflammatory Bowel DiseaseChristina Schräpel, Lukas Kovar, Dominik Selzer, et al.
Pageof 36

Showing results (61-70 of 352) with videos related to

Sort By:
Pageof 36
Alimentary Pharmacology & Therapeutics|February 15, 2022
Resolution of dominant patient-reported outcome at end of induction predicts clinical and endoscopic remission in Crohn's diseaseEmily C L Wong, Parambir S Dulai, John K Marshall, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|August 27, 2022
Predictors of Placebo Induction Response and Remission in Ulcerative ColitisEmily C L Wong, Parambir S Dulai, John K Marshall, et al.
Inflammatory Bowel Diseases|August 3, 2022
Comparative Efficacy of Infliximab vs Ustekinumab for Maintenance of Clinical Response in Biologic Naïve Crohn's DiseaseEmily C L Wong, Parambir S Dulai, John K Marshall, et al.
Plos One|May 28, 2020
Risk for development of inflammatory bowel disease under inhibition of interleukin 17: A systematic review and meta-analysisJohan Burisch, Wolfgang Eigner, Stefan Schreiber, et al.
Scandinavian Journal of Gastroenterology|August 1, 2022
End of induction patient reported outcomes predict clinical remission and endoscopic improvement with vedolizumab and adalimumab in ulcerative colitisEmily Chu Lee Wong, Badar Hasan, Parambir S Dulai, et al.
Inflammatory Bowel Diseases|November 25, 2022
Predictors of Clinical Remission to Placebo in Clinical Trials of Crohn's DiseaseEmily C L Wong, Parambir S Dulai, John K Marshall, et al.
Analytical Chemistry|January 7, 2012
Simultaneous quantification of eleven thiopurine nucleotides by liquid chromatography-tandem mass spectrometryUte Hofmann, Georg Heinkele, Sieglinde Angelberger, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|September 15, 2014
Placebo response rate in clinical trials of fistulizing Crohn's disease: systematic review and meta-analysisAlexander C Ford, Pavit Luthra, Stephen B Hanauer, et al.
Zeitschrift Fur Gastroenterologie|January 12, 2026
Post-induction serum vedolizumab levels are not associated with better maintenance outcomes in patients with Crohn's diseaseJagoda Pokryszka, Christian Primas, Michael Stadlmann, et al.
Pharmaceutics|September 28, 2021
External Model Performance Evaluation of Twelve Infliximab Population Pharmacokinetic Models in Patients with Inflammatory Bowel DiseaseChristina Schräpel, Lukas Kovar, Dominik Selzer, et al.
Pageof 36